Drug Trial Radar · NCT06660667
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Nov 21, 2024
Primary completion
May 18, 2027
Study completion Jun 30, 2031
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration. Participants will be enrolled in one of 2 parts: * In Part I (dose escalation), multiple dose levels of SAR402663 will be evaluated in successive cohorts of participants * In Part II (dose expansion), participants will be randomized to receive one of two dose levels selected based on data from Part I. Participants, investigators and outcomes assessors will be masked to dose. After receiving one-time dose of SAR402663, participants will undergo regular assessments over 12 months. Following this, participants will enter an extended follow-up (EFU) phase for the assessment of safety and durability of clinical activity of SAR402663 through Year 5.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
SAR402663Biological
Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection
DiluentDrug
Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of ocular treatment emergent adverse event (TEAEs)Time frame: Day 1 to Week 52
- Incidence and severity of ocular treatment emergent serious adverse event (TESAEs)Time frame: Day 1 to Week 52
- Incidence and severity of non-ocular TEAEsTime frame: Day 1 to Week 52
- Incidence and severity of non-ocular TESAEsTime frame: Day 1 to Week 52
- Number of participants with any clinically significant changes in laboratory variablesTime frame: Day 1 to Week 52
- Number of participants with any clinically significant changes in vital signsTime frame: Day 1 to Week 52
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
Associated Retina Consultants - Phoenix- Site Number : 8400011
Phoenix, Arizona
Retina Macula Institute of Arizona- Site Number : 8400028
Scottsdale, Arizona
California Retina Consultants - Bakersfield- Site Number : 8400001
Bakersfield, California
Retina-Vitreous Associates Medical Group - Beverly Hills- Site Number : 8400023
Beverly Hills, California
Vitreo Retinal Associates - Gainesville- Site Number : 8400004
Gainesville, Florida
Retina Vitreous Associates of Florida - St. Petersburg- Site Number : 8400002
St. Petersburg, Florida
Southeast Retina Center- Site Number : 8400010
Augusta, Georgia
University Retina - Lemont- Site Number : 8400005
Lemont, Illinois
Cumberland Valley Retina Consultants - Hagerstown- Site Number : 8400003
Hagerstown, Maryland
Retina Specialist- Site Number : 8400020
Towson, Maryland
Ophthalmic Consultants of Boston - Boston- Site Number : 8400009
Boston, Massachusetts
Sierra Eye Associates- Site Number : 8400021
Reno, Nevada
North Carolina (Nc) Retina Associates - Wake Forest Office- Site Number : 8400033
Wake Forest, North Carolina
Oregon Retina- Site Number : 8400017
Eugene, Oregon
Mid Atlantic Retina- Site Number : 8400032
Bethlehem, Pennsylvania
Charleston Neuroscience Institute - Ladson- Site Number : 8400016
Ladson, South Carolina
Charles Retina Institution- Site Number : 8400018
Germantown, Tennessee
Retina Research Institute of Texas- Site Number : 8400008
Abilene, Texas
Austin Research Center for Retina- Site Number : 8400015
Austin, Texas
Austin Clinical Research - Austin - Anderson Mill Road- Site Number : 8400007
Austin, Texas
Texas Retina Associates - Dallas- Site Number : 8400006
Dallas, Texas
Medical Center Ophthalmology Associates- Site Number : 8400030
San Antonio, Texas
Retinal Consultants of Texas - San Antonio- Site Number : 8400012
San Antonio, Texas
Retina Consultants of Texas - The Woodlands- Site Number : 8400019
The Woodlands, Texas
Investigational Site Number : 8260027
Liverpool, United Kingdom
Investigational Site Number : 8260024
London, Westminster, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.